Clinical Trial Update: Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis [Phase 4]

View source ↗

Summary

Open-label Phase 4 safety study evaluating imiquimod 5% cream for large areas of actinic keratosis has completed and results were posted in 2008.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Graceway Pharmaceuticals, LLC | Conditions: Keratosis | Phase 4 | Status: COMPLETED | Results posted: 2008-11-25